WEST PHARMACEUTICAL SERVICES INC
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
About West Pharmaceutical Services
Surgical & Medical Instruments & Apparatus, SIC 3841
West Pharmaceutical Services, Inc. designs and manufactures containment and delivery systems for injectable drugs and healthcare products. The company operates through two segments: Proprietary Products and Contract-Manufactured Products. Its Proprietary Products segment provides primary packaging components such as stoppers, seals, syringes, and cartridges, alongside drug delivery devices, reconstitution systems, and analytical lab services. The Contract-Manufactured Products segment provides custom design, molding, and automated assembly of complex devices used in surgical, ophthalmic, diagnostic, and drug delivery applications. West serves leading biologic, generic, pharmaceutical, diagnostic, and medical device companies worldwide.
The company is headquartered in Exton, Pennsylvania, and operates manufacturing facilities across North America, South America, Europe, and Asia, alongside affiliates in Japan and Mexico. As of year-end 2025, West employed approximately 10,800 people globally across its proprietary, contract manufacturing, and corporate operations.
Summary of the business section of West Pharmaceutical Services's latest annual report, written by StockData.
Company profile
Company
- Legal name
- WEST PHARMACEUTICAL SERVICES INC
- Headquarters
- Exton, PA
- Address
- 530 Herman O. West Drive 19341
- Phone
- (610) 594-2900
- Website
- westpharma.com
- Employees
- 10,800, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Pennsylvania
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- WST
- Exchange
- NYSE
- Shares outstanding
- 70M, Jul 20, 2026
- Public float
- $15.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Nov 4, 2013; 2-for-1, Sep 27, 2013; 2-for-1, Sep 29, 2004; 2-for-1, Jun 2, 1987; 2-for-1, May 6, 1982
- SEC CIK
- 105770
- CUSIP
- 955306105
- ISIN
- US9553061055
- LEI
- 5493007NKRGM1RJQ1P16
- EIN
- 23-1210010
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michel Lagarde | President and CEO, Director | 7,850 |
| Eric Mark Green | President, CEO and Board Chair, Director | 175,418 |
| Annette F. Favorite | Sr. VP & Chief HR Officer | 29,308 |
| Robert W. McMahon | SVP & Chief Financial Officer | 3,429 |
| Shane Alden Campbell | SVP, Proprietary Segment | 274 |
| Chad Winters | VP, Chief Accounting Officer | 2,419 |
| Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | 691 |
| Norman D. Finch Jr. | SVP, GC & Corporate Secretary | – |
| Charles Witherspoon | VP & Treasurer | 1,430 |
| Cindy Reiss-Clark | Chief Commercial Officer | 5,131 |
| Bernard Birkett | Sr VP, Chief Financial Officer | 7,669 |
| Kimberly Banks MacKay | SVP, GC & Corporate Secretary | 1,605 |
| Silji Abraham | SVP, Chief Technology Officer | 3,138 |
| Janet Brutschea Haugen | Director | 2,113 |
| Molly Joseph | Director | 4,398 |
| Douglas A. Michels | Director | 46,496 |
| Robert F. Friel | Director | 5,513 |
| William F. Feehery | Director | 32,519 |
| Deborah L. Keller | Director | 11,560 |
| Paolo Pucci | Director | 11,854 |
| Goldman Myla Lai | Director | 20,435 |
| Mark A. Buthman | Director | 44,309 |
| Stephen H. Lockhart | Director | 3,523 |
| Thomas W. Hofmann | Director | 44,637 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Eric M. Green | $7.19M | $4.12M | $3.80M | $59 | $118 |
| FY2024 Eric M. Green | $8.39M | $5.25M | $1.75M | $70 | $103 |
| FY2023 Eric M. Green | $9.42M | $16.99M | $2.08M | $75 | $100 |
| FY2022 Eric M. Green | $7.91M | -$12.07M | $1.77M | $50 | $98 |
| FY2021 Eric M. Green | $9.47M | $35.10M | $2.00M | $100 | $100 |
| FY2020 Eric Green | $7.64M | $30.52M | $1.87M | $100 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 10,800 people, excluding contractors and temporary workers, in our operations throughout the world.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 7, 2005 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 3, 2005 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 25, 2005 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 14, 2005 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 11, 1999 | Name change | Name changed from WEST CO INC to WEST PHARMACEUTICAL SERVICES INC |
| Mar 31, 1998 | Late filing | Notification of late filing |